Pan-Cancer Potential! Jiangsu Vcare’s Anti-Resistant TRK Inhibitor VC004 Capsule advances to NDA Preparation Phase
Published Time:
2025-01-26 18:06
Source:
In January 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that its self-developed next-generation anti-resistant TRK inhibitor VC004 capsule has officially entered the domestic NDA preparation phase, initiating pre-NDA communications with regulatory authorities. Marking this milestone, Jiangsu Vcare has joined the top tier of domestic self-developed drugs targeting this pathway at remarkable speed.
VC004 is clinically indicated for the treatment of NTRK fusion-positive solid tumors. It features a "tumor-agnostic" mechanism and has demonstrated outstanding efficacy and favorable safety in Phase I/II clinical studies.
The Phase I data were presented at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024):
In treatment-naïve patients, the confirmed objective response rate (ORR) in the recommended Phase II dose (RP2D) expansion cohort was 73.1% [95% CI: 52.2–88.4]. Among three patients who had progressed on prior TRK-TKI therapy, two showed tumor shrinkage, with one achieving a partial response (PR, 39.6%).
Most patients experienced rapid onset and sustained clinical benefits, with the longest-to-date duration of response exceeding 36 months. Among six patients with baseline brain metastases, two exhibited intracranial lesion reductions of 61.8% and 25%, respectively, while two others showed complete disappearance of non-target lesions after four months of treatment.
Safety-wise, treatment-related adverse events (TRAEs) were predominantly Grade 1–2, with no fatal TRAEs reported. No new safety signals were observed compared to other drugs in the same class.
About VC004
VC004 is a Class 1 targeted anti-tumor drug, independently developed by Jiangsu Vcare. As a next-generation TRK inhibitor with a unique anti-resistance mechanism, it is poised to become a new treatment option for patients with NTRK fusion mutations. In China, the project is advancing with a single-arm Phase II trial as the pivotal study, while its Investigational New Drug (IND) application has been approved by the US FDA. Currently, no second-generation NTRK inhibitor matches the efficacy of first-generation drugs on NTRK-naïve patients and possesses second-generation anti-drug resistance activity, positioning VC004 as a front-runner in this category.
Related News
28
2025
/
04
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful enrollment of the first participant in its Phase II clinical trial for VC005 topical gel, a self-developed next-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD). The trial aims to evaluate the efficacy of VC005 gel in adult patients with mild-to-moderate AD, providing a critical data for dose selection in future clinical studies and further assesses the drug's safety profile.
View Details
11
2025
/
04
Recently, following joint review by Nanjing Jiangbei New Area Sci-Tech Bureau and Nanjing Municipal Science and Technology Bureau, the"Nanjing Key Laboratory for Artificial Intelligence (AI) Drug Design"established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was approved as a 2025 Nanjing Key Laboratory. This marks authoritative recognition of Jiangsu Vcare’s scientific capabilities, with the Lab having achieved significant progress in drug design and molecular discovery.
View Details
26
2025
/
03
Jiangsu Vcare Launches Phase II Trial for VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
On March 26, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) officially launched the Phase II clinical trial for its self-developed, highly selective JAK1 inhibitor VC005 gel for the topical treatment of mild-to-moderate atopic dermatitis (AD). The completed Phase I clinical study of VC005 gel demonstrated excellent safety and significant efficacy.
View Details
27
2025
/
01
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
View Details
26
2025
/
01
In January 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that its self-developed next-generation anti-resistant TRK inhibitor VC004 capsule has officially entered the domestic NDA preparation phase, initiating pre-NDA communications with regulatory authorities. Marking this milestone, Jiangsu Vcare has joined the top tier of domestic self-developed drugs targeting this pathway at remarkable speed.
View Details
22
2025
/
01
Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn